{
    "2019-07-11": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates",
                "features": {
                    "keywords": [
                        "drug distributors",
                        "drug makers",
                        "Trump",
                        "rebates"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal",
                "features": {
                    "keywords": [
                        "medical stocks",
                        "Federal Judge",
                        "Trump Proposal"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "4 Drug Stocks Getting Smashed",
                "features": {
                    "keywords": [
                        "drug stocks",
                        "smashed"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Bank of America",
                        "Eli Lilly",
                        "Boston Scientific",
                        "Schwab",
                        "Advanced Micro Devices"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "UPDATE 1-Eli Lilly's bio-medicines head to leave next month",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "bio-medicines",
                        "head",
                        "leave"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Eli Lilly's bio-medicines head to leave next month",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "bio-medicines",
                        "head",
                        "leave"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Lilly Announces Changes in Senior Leadership",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Senior Leadership",
                        "Changes"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "New England Journal of Medicine Publishes Positive Phase 3 Data for EmgalityÂ® (galcanezumab-gnlm) in Episodic Cluster Headache",
                "features": {
                    "keywords": [
                        "New England Journal of Medicine",
                        "Phase 3 Data",
                        "Emgality",
                        "galcanezumab-gnlm",
                        "Episodic Cluster Headache"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Stocks - Health Insurers Drive Dow to New Record at Opening",
                "features": {
                    "keywords": [
                        "Health Insurers",
                        "Dow",
                        "Record",
                        "Opening"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}